Pennsylvania Medicaid & Suboxone Coverage in 2026

If you're navigating opioid use disorder treatment in Pennsylvania, you've probably heard that Medicaid covers Suboxone — but the details matter. Pennsylvania's Medical Assistance (MA) program covers buprenorphine products, but your experience will depend on which managed care organization (MCO) you're enrolled in, where you live, and whether your provider participates in the state's Centers of Excellence network.

Pennsylvania took a major step forward in 2016 by launching the Centers of Excellence (COE) for Opioid Use Disorder. This model connects Medicaid recipients to comprehensive, evidence-based treatment without the maze of prior authorizations that plague other states. If you qualify for Pennsylvania Medicaid and need treatment, understanding how this system works can make the difference between starting care this week or waiting months.

This guide breaks down exactly what Pennsylvania Medicaid covers for Suboxone and buprenorphine treatment, how the COE model works, what managed care plans operate in your county, and how to access same-day telehealth care through providers like Grata Health.

Does Pennsylvania Medicaid Cover Suboxone?

Yes. Pennsylvania Medical Assistance covers all FDA-approved buprenorphine products for opioid use disorder, including Suboxone (buprenorphine/naloxone) films, generic buprenorphine/naloxone tablets and films, Zubsolv sublingual tablets, and Sublocade injections.

Unlike some states that require extensive prior authorization for every patient, Pennsylvania has streamlined access through its Centers of Excellence model. If you receive treatment through a COE-participating provider, you typically won't face prior authorization barriers for your first prescription or ongoing medication.

However, coverage specifics can vary depending on your managed care plan. Pennsylvania contracts with five major MCOs that administer Medicaid benefits: UPMC Community HealthChoices, Geisinger Health Plan, AmeriHealth Caritas, Highmark Wholecare, and Pennsylvania Health & Wellness (Centene). Each MCO maintains its own formulary (preferred drug list) and may have different requirements for certain buprenorphine products.

For the most current coverage information, see our broader guide on Medicaid coverage for Suboxone nationwide.

Pennsylvania's Centers of Excellence Model

Pennsylvania's Centers of Excellence for Opioid Use Disorder represent one of the most patient-friendly Medicaid addiction treatment systems in the country. Launched as part of the state's response to the opioid crisis, the COE model designates specific treatment sites that meet rigorous standards for medication-assisted treatment (MAT) and wraparound services.

When you receive care through a designated COE, you get:

• Immediate access to buprenorphine without prior authorization delays
• Coordinated behavioral health services including counseling and peer support
• Case management to help with housing, transportation, and other barriers
• Harm reduction services including naloxone distribution and fentanyl test strips
• Family support programs that help rebuild relationships during recovery

The COE model recognizes that addiction treatment works best when it's comprehensive and low-barrier. Rather than making you jump through administrative hoops to prove you "deserve" medication, COEs focus on getting you started quickly and supporting you through the entire recovery process.

To find a Center of Excellence near you, contact your managed care plan's member services line or ask your primary care provider for a referral. Many COEs also accept walk-ins for initial assessment, especially if you're in withdrawal or crisis.

Which Managed Care Plan Covers You?

Pennsylvania's Medicaid program operates through HealthChoices, a managed care system that assigns beneficiaries to one of five MCOs based on their county of residence. Your managed care plan determines which specific buprenorphine products are preferred, whether you need prior authorization for certain formulations, and which providers are in-network.

UPMC Community HealthChoices serves the southwestern and north-central regions of Pennsylvania. UPMC's formulary lists buprenorphine/naloxone generics as preferred without prior authorization. Brand-name Suboxone and Zubsolv may require prior authorization unless prescribed through a COE. Sublocade injections typically need prior authorization showing trial of sublingual products first.

Geisinger Health Plan covers central and northeastern Pennsylvania counties. Geisinger maintains one of the most straightforward buprenorphine policies — generic films and tablets are preferred, with minimal barriers for patients in COE programs. They've also integrated addiction medicine specialists into their primary care network, making it easier to start treatment with your regular doctor.

AmeriHealth Caritas serves southeastern Pennsylvania including Philadelphia. Their formulary prioritizes generic buprenorphine/naloxone products, but they've been expanding coverage for Sublocade monthly injections as clinical evidence supports their effectiveness for patients who struggle with daily dosing. Philadelphia residents also benefit from the city's extensive COE network and harm reduction programs.

Highmark Wholecare operates in multiple regions across the state. Highmark has partnered with several telehealth providers to expand access to buprenorphine prescribers, particularly in rural counties where addiction specialists are scarce. For more on Highmark's addiction treatment policies, see our Highmark Suboxone coverage guide.

Pennsylvania Health & Wellness (Centene) covers various counties statewide. As part of the national Centene network, they follow evidence-based prior authorization criteria for MAT, generally approving initial prescriptions without barriers and requiring step therapy only for more expensive brand-name products when generics are available.

You can verify which plan you're enrolled in by checking your Medicaid card or calling Pennsylvania's Medicaid helpline at 1-800-692-7462.

Preferred Drug List & Prior Authorization

Each Pennsylvania Medicaid MCO maintains a Preferred Drug List (PDL) that determines coverage tiers and prior authorization requirements. Understanding where your medication falls on the PDL helps you avoid unexpected denials or delays.

First-line (preferred) products across most Pennsylvania MCOs include:

• Generic buprenorphine/naloxone sublingual films (8mg/2mg, 2mg/0.5mg)
• Generic buprenorphine/naloxone tablets (8mg/2mg, 2mg/0.5mg)
• Buprenorphine monoproduct tablets (for pregnant patients)

These products typically require no prior authorization when prescribed by a COE provider or by a qualified buprenorphine prescriber for a documented opioid use disorder diagnosis.

Products that may require prior authorization include:

• Brand-name Suboxone films (when generic equivalent exists)
• Zubsolv sublingual tablets (higher-strength formulations)
• Sublocade monthly injections (usually requires trial of sublingual products first)
• Buprenorphine buccal films (Bunavail)

Prior authorization criteria typically require documentation that generic sublingual products were tried first or are not appropriate due to specific clinical circumstances. For example, Sublocade approval might require showing adherence challenges with daily dosing or past success on sublingual buprenorphine that could be maintained more effectively with monthly injections.

If your doctor prescribes a product requiring prior authorization, they'll need to submit clinical documentation to your MCO. This process usually takes 1-3 business days for standard requests or 24 hours for expedited reviews when you're in withdrawal or immediate medical need.

For a deeper dive into how prior authorization works across insurance types, read our guide on prior authorization for Suboxone explained.

Behavioral Health Carve-Outs & COE Access

Pennsylvania carved behavioral health services out of standard Medicaid managed care in many regions, creating separate systems for mental health and substance use treatment. This means your addiction treatment might be managed differently than your medical care, depending on your county.

In counties with behavioral health carve-outs, your mental health and addiction services are coordinated through a separate entity called a Behavioral Health Managed Care Organization (BH-MCO). These organizations work in parallel with your physical health MCO but handle authorization and provider networks for behavioral health specifically.

For example, Community Care Behavioral Health serves as the BH-MCO for many western Pennsylvania counties. If you live in Allegheny County and have UPMC for physical health, Community Care would coordinate your addiction treatment, including approvals for residential programs or intensive outpatient services that complement your Suboxone prescription.

The Centers of Excellence model bridges this gap. COEs are designed to provide integrated care regardless of whether your county has a carve-out. When you enter treatment through a COE, the facility coordinates with both your physical health MCO (for buprenorphine coverage) and your BH-MCO (for counseling, case management, and other services) so you don't have to navigate two separate systems.

This integration is especially valuable if you have co-occurring mental health conditions. Many people with opioid use disorder also experience depression, anxiety, or PTSD. COE providers can prescribe medications for these conditions alongside your buprenorphine and ensure your treatment plans work together rather than in isolation.

If you're not sure whether your county has a behavioral health carve-out or which organization manages your addiction treatment benefits, call your MCO's member services line or ask your provider to verify your coverage before starting treatment.

Getting started with Suboxone treatment through Pennsylvania Medicaid is often simpler than navigating the system alone — Grata Health verifies your coverage and handles authorization paperwork so you can focus on recovery.

Coverage in Philadelphia, Pittsburgh, and Rural Counties

Pennsylvania's geography creates stark differences in addiction treatment access. Urban centers like Philadelphia and Pittsburgh have extensive COE networks, multiple telehealth providers, and robust harm reduction programs. Rural counties often have fewer providers, longer wait times, and less infrastructure for same-day access.

Philadelphia has one of the highest concentrations of Centers of Excellence in the state. The city has also invested heavily in harm reduction, including syringe services programs and overdose prevention sites. If you live in Philadelphia and have AmeriHealth Caritas or Pennsylvania Health & Wellness, you can typically start treatment within days of deciding you're ready. Many Philadelphia COEs also offer walk-in assessments and same-day buprenorphine induction.

The city's Department of Behavioral Health and Intellectual disAbility Services (DBHIDS) coordinates Philadelphia's addiction treatment system and maintains a warm handoff program that connects people leaving emergency departments after overdoses directly to COE treatment slots.

Pittsburgh and Allegheny County have similarly robust networks, with UPMC Community HealthChoices covering most Medicaid beneficiaries. Allegheny County's behavioral health carve-out (managed by Community Care) has streamlined MAT access, and many primary care practices now prescribe buprenorphine as part of routine care. Pittsburgh also benefits from strong university hospital systems that integrate addiction medicine into family medicine training.

Rural Pennsylvania faces greater challenges. Counties in north-central and northeastern regions often have only one or two buprenorphine prescribers, creating wait lists that can stretch weeks or months. Transportation barriers compound the problem — getting to a provider 45 minutes away for weekly appointments isn't feasible for many rural residents without reliable cars or public transit.

This is where telehealth becomes essential. Pennsylvania expanded telehealth flexibilities during the pandemic and has maintained many of those policies, allowing qualified providers to prescribe buprenorphine via video visit without requiring an initial in-person exam. For rural Medicaid beneficiaries, this means you can start treatment with a Pennsylvania telehealth provider like Grata Health the same day you decide you're ready, regardless of whether there's a local prescriber.

Grata Health serves patients across Pennsylvania, including rural counties in our coverage areas. We accept all major Pennsylvania Medicaid MCOs and coordinate with COE networks to ensure you get both medication and wraparound support.

How to Start Suboxone Treatment with PA Medicaid

Starting buprenorphine treatment through Pennsylvania Medicaid is more straightforward than many people expect, especially if you use a provider who participates in the Centers of Excellence model or specializes in telehealth MAT.

Step 1: Verify your Medicaid eligibility and MCO enrollment. Check your Medicaid card or call 1-800-692-7462 to confirm you're enrolled in one of the five managed care plans and that your coverage is active. If you're newly eligible or recently moved, make sure your address is updated so you're assigned to the correct county plan.

Step 2: Choose between in-person COE care or telehealth treatment. If you prefer face-to-face appointments and live near a Center of Excellence, contact them directly for an intake appointment. Many COEs can see you within 48-72 hours. If you live in a rural area, have transportation challenges, or simply prefer the convenience of video appointments, consider telehealth providers who accept Pennsylvania Medicaid.

Step 3: Complete your intake assessment. Whether in-person or via video, your first appointment will cover your opioid use history, current symptoms, other medications, and medical conditions. Your provider will assess whether buprenorphine is appropriate and discuss what to expect during induction (the first few days when you start the medication). This assessment typically takes 30-45 minutes.

Step 4: Coordinate pharmacy coverage. Your provider will send your prescription to a pharmacy that accepts Pennsylvania Medicaid. Most major chains (CVS, Rite Aid, Giant, Walmart) participate in Medicaid pharmacy networks, but call ahead to confirm they have buprenorphine in stock. Generic films and tablets typically have no copay for Medicaid recipients, though some brand products might have small copays depending on your MCO.

Step 5: Begin treatment and follow-up care. You'll typically start on a lower dose and increase gradually over the first few days until you find the right amount to eliminate cravings and withdrawal without side effects. Your provider will want to see you frequently at first — usually weekly for the first month — then less often as you stabilize. Pennsylvania Medicaid covers these follow-up visits without limits when they're medically necessary.

For a detailed walkthrough of what happens at your first appointment, see our guide on what to expect at your first telehealth addiction appointment.

Generic vs. Brand-Name: What PA Medicaid Prefers

Pennsylvania Medicaid MCOs universally prefer generic buprenorphine/naloxone products over brand-name Suboxone, primarily for cost reasons. The medication is identical — same active ingredients, same FDA approval, same effectiveness — but generics cost a fraction of brand-name products.

Most patients do perfectly fine on generics. The sublingual films dissolve the same way, taste similar, and deliver the same therapeutic effect. If your provider prescribes "buprenorphine/naloxone sublingual film 8mg/2mg," you'll receive whatever manufacturer your pharmacy stocks, which changes based on their distributor contracts.

However, some patients have legitimate medical reasons to prefer brand-name Suboxone. These might include:

• Sensitivity to inactive ingredients that differ between manufacturers
• Consistency concerns when pharmacies frequently switch generic suppliers
• Prior success on brand-name product with difficulty tolerating generic switches

If you have a documented medical reason to stay on brand-name Suboxone, your doctor can request prior authorization from your MCO. They'll need to document why generic alternatives aren't appropriate — for instance, if you developed a rash with one generic formulation or experienced return of withdrawal symptoms when your pharmacy switched manufacturers mid-treatment.

Most Pennsylvania MCOs will approve brand-name Suboxone when there's clear clinical justification, though you might face a small copay. The prior authorization process typically takes 1-3 days.

For more on the differences between formulations, read our comparison of generic buprenorphine vs. brand-name Suboxone.

Sublocade Coverage for Monthly Injections

Sublocade — the monthly buprenorphine injection — represents a newer treatment option that's gaining traction in Pennsylvania Medicaid coverage policies. Instead of taking daily sublingual films, you receive a subcutaneous injection once a month that maintains steady buprenorphine levels.

Pennsylvania MCOs generally require prior authorization for Sublocade, with typical approval criteria including:

• At least 7 days of stable treatment on sublingual buprenorphine (to confirm you tolerate the medication)
• Documentation of adherence challenges with daily dosing, such as difficulty remembering daily medication or losing tablets/films
• Clinical justification for monthly injections, like frequent travel for work or living situations that make daily medication storage difficult

The prior authorization barrier exists mainly